| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01713978 |
| P698 | PubMed publication ID | 7699151 |
| P2093 | author name string | Wilson AP | |
| Grüneberg RN | |||
| P2860 | cites work | Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 | Q24671879 |
| Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
| Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity | Q28326763 | ||
| Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis | Q28333659 | ||
| Transferable vancomycin and teicoplanin resistance in Enterococcus faecium | Q34042099 | ||
| Vancomycin therapy for infective endocarditis | Q34284955 | ||
| In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer | Q35281149 | ||
| Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters | Q35341106 | ||
| Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci | Q35361659 | ||
| Pharmacokinetics of teicoplanin in renal failure | Q35541154 | ||
| Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria | Q35648347 | ||
| Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci | Q35885570 | ||
| Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon | Q36752580 | ||
| Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts | Q36753066 | ||
| Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States | Q36753208 | ||
| Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin | Q36753928 | ||
| A review of the safety profile of teicoplanin | Q37091081 | ||
| Screening and treatment of infections caused by resistant enterococci | Q37711795 | ||
| Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential | Q37860938 | ||
| Pharmacokinetics and pharmacodynamics in critically ill patients | Q39657128 | ||
| Dosage recommendations for teicoplanin | Q40733986 | ||
| Pharmacokinetics of teicoplanin in hemodialysis patients | Q40745183 | ||
| A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients | Q40755970 | ||
| Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections | Q41333638 | ||
| A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria | Q42067909 | ||
| Clinical and Microbiologic Aspects of Serious Infections Caused by Staphylococcus Epidermidis | Q43652825 | ||
| Emergence of vancomycin resistance in coagulase-negative staphylococci | Q44441075 | ||
| Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results | Q44785496 | ||
| In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies | Q45087507 | ||
| Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases | Q45156883 | ||
| Two distinct forms of vancomycin resistance amongst enterococci in the UK. | Q54332106 | ||
| Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. | Q54334089 | ||
| World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. | Q54357571 | ||
| Teicoplanin in infections caused by methicillin-resistant staphylococci. | Q54394419 | ||
| The effect of selective decontamination of the digestive tract on gastrointestinal enterococcal colonization in ITU patients | Q67472943 | ||
| Enterococcus species in urinary tract infection | Q67547316 | ||
| A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies | Q67905926 | ||
| Enterococcus faecium sensitive to teicoplanin but not vancomycin | Q68322225 | ||
| Comparison of two methods of bacteriologic sampling of the lower respiratory tract: a study in ventilated patients with nosocomial bronchopneumonia | Q69586654 | ||
| Does antibiotic prophylaxis at the time of catheter insertion reduce the incidence of catheter-related sepsis in intravenous nutrition? | Q69875877 | ||
| Nosocomial infections | Q70293887 | ||
| Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients | Q70600377 | ||
| Coagulase-negative staphylococcal bacteraemia treated with teicoplanin | Q70695372 | ||
| Vancomycin pharmacokinetics in critically ill patients | Q70736458 | ||
| Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage | Q72417776 | ||
| Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial | Q81605507 | ||
| The bactericidal activity of vancomycin and teicoplanin against methicillin-resistant strains of coagulase negative Staphylococcus spp | Q93516151 | ||
| Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function | Q93516167 | ||
| Nosocomial infections in intensive care units | Q93673060 | ||
| P304 | page(s) | S17-22 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Anti-infective treatment in intensive care: the role of glycopeptides | |
| P478 | volume | 20 Suppl 4 |
| Q54059177 | Clinical impact of rapid oxacillin susceptibility testing using a PCR assay in Staphylococcus aureus bactaeremia. |
| Q28769501 | Decreasing antibiotic overuse in neonatal intensive care units: quality improvement research |
| Q54122404 | European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. |
| Q74217487 | Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns |
| Q34803032 | Pathogenesis of urinary tract infections: a review |
| Q35228977 | Prospective observational evaluation of incidences and implications of drug-drug interactions induced adverse drug reactions in critically ill patients |
| Q35826283 | Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration |
Search more.